LGALS3 and Shock: Seven are known or predicted to be druggable by conventional therapeutic modalities, and therapeutic agents targeting 2 of the identified proteins are currently under evaluation in phase II clinical trials: adrecizumab, an ADM agonist, for acute HF and cardiogenic shock,55 and modified citrus pectin, a Gal-3 antagonist, for cardiac fibrosis.56 We note that CTSL1 inhibition has been proposed as a potential treatment for COVID-1966; our results signal HF as a potential safety liability of this therapeutic approach.